Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy|
|Citation:||Immunological Reviews, 2015; 263(1):257-278|
|Christopher N. Hahn, Parvathy Venugopal, Hamish S. Scott, Devendra K. Hiwase|
|Abstract:||Differential splicing contributes to the vast complexity of mRNA transcripts and protein isoforms that are necessary for cellular homeostasis and response to developmental cues and external signals. The hematopoietic system provides an exquisite example of this. Recently, discovery of mutations in components of the spliceosome in various hematopoietic malignancies (HMs) has led to an explosion in knowledge of the role of splicing and splice factors in HMs and other cancers. A better understanding of the mechanisms by which alternative splicing and aberrant splicing contributes to the leukemogenic process will enable more efficacious targeted approaches to tackle these often difficult to treat diseases. The clinical implications are only just starting to be realized with novel drug targets and therapeutic strategies open to exploitation for patient benefit.|
|Keywords:||alternative splicing; splice factors; leukemogenesis; hematopoietic malignancy; hematopoiesis|
|Description:||Article first published online: 15 DEC 2014|
|Rights:||© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.